Mentions
Extended reach
Total likes
Video views
AI synopsis
Many discussions highlight the modest efficacy of esketamine as a treatment, with phrases such as 'small benefit' and 'disappointing results' pointing to skepticism about its effectiveness. The repeated references to concerns about the treatment's impact on suicidality and potential long-term effects further illustrate a critical tone among participants who express lingering doubts about the FDA's approval of this method.
Overall, the discussions tend to express a cautious agreement regarding the findings, indicating a recognition of the limitations of the treatment.
Participants show high interest, as many discussions delve into the implications and details of the study.
While the depth of engagement is moderate, many users reference specific data from the study, suggesting a focused discussion around the topic.
There is a strong consensus that the research implies significant implications for the treatment landscape of depression.
Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to antipsychotic aug, declines over time > Maintenance trials may be biased by WD effects (49% of relapses occurred in 1st 4 wk after stop) https://t.co/NjeEEmNgPO https://t.co/4KEA5rDxhv
Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extraordinarias expectativas que resultan falsas. https://t.co/nRSrxLNolb
うつ病へのエスケタミン増強のシステマティックレビュー&メタ解析。あんまりパッとしないかぁ。ゲームチェンジャーとまでは言えなさそう。 Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry https://t.co/KnlGf6Hwka
Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5qfyxne https://t.co/5bC8ONNrds
New PRISMA review of esketamine's effects on depression has basically pretty disappointing results. "Weak but significant" effects. pubmed.ncbi.nlm.nih.gov/39876682/
While esketamine has been approved by the FDA for treatment-resistant depression, a review of findings suggests that the efficacy of esketamine as an add-on to antidepressants is modest. https://t.co/5nQ5f89ct3 https://t.co/6Ha9XvchGj
This video discusses the efficacy differences between intravenous and intranasal esketamine for treating depression. A recent study highlights modest effects on symptoms and raises concerns about safety and potential…
Endovenous or intranasal: What is the best method for ketamine in treatment-resistant depression? Dr. Tiago Gil uncovers the differences between these two administration routes while emphasizing the importance of safety…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
https://t.co/b2d0x6A8MU
RT @SEPsiq: Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry ht…
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry https://t.co/RDdTM80QFE
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
Meta-Análisis pone de manifiesto que el tamaño de efecto de esketamina como antidepresivo es aprox.=0.2 y NULO para un supuesto efecto antisuicida. La referencia para cierta significación clínica sería 0.5: no llega ni a la mitad del mínimo. #esketamina pubmed.ncbi.nlm.nih.gov/39876682/
@PloederlM https://t.co/buMZWXdLoK
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
‘The study findings suggest that esketamine’s efficacy as an add-on to antidepressants is modest in treatment-resistant depression (similar to augmentation strategies with atypical antipsychotics) and is absent against suicidality itself’ https://t.co/yjUixUOKk9
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
pubmed.ncbi.nlm.nih.gov/39876682/?
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis - PubMed https://t.co/uZQRRifuWI
https://t.co/sxsJHqF43y
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
#DepresiónResistente: Estudio que sugiere una modesta Eficacia de la #Esketamina como complemento de otros Antidepresivos. Vía @SEPsiqLegal https://t.co/xXcRv0lY7B
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @jose_valdecasas: Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5…
Metaanálisis recién publicado en el American Journal sobre tratamiento con esketamina en depresión: https://t.co/FMy5qfyxne https://t.co/5bC8ONNrds
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
RT @psiquicritic: Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extr…
Auge y caída de la esketamina. La historia se repite una y otra vez: industria farmacéutica y psiquiatras crean unas extraordinarias expectativas que resultan falsas. https://t.co/nRSrxLNolb
RT @Robson_1915: うつ病へのエスケタミン増強のシステマティックレビュー&メタ解析。あんまりパッとしないかぁ。ゲームチェンジャーとまでは言えなさそう。 Esketamine Treatment for Depression in Adults: A PRISMA…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
うつ病へのエスケタミン増強のシステマティックレビュー&メタ解析。あんまりパッとしないかぁ。ゲームチェンジャーとまでは言えなさそう。 Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry https://t.co/KnlGf6Hwka
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
A fascinating finding sheds light on the constructive effects of Esketamine! https://t.co/Uc9JDBW9Xx
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis https://t.co/gF9spMfjBl
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
While esketamine has been approved by the FDA for treatment-resistant depression, a review of findings suggests that the efficacy of esketamine as an add-on to antidepressants is modest. https://t.co/5nQ5f89ct3 https://t.co/6Ha9XvchGj
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
New PRISMA review of esketamine's effects on depression has basically pretty disappointing results. "Weak but significant" effects. pubmed.ncbi.nlm.nih.gov/39876682/
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
Esketamin büyük umutlarla tedaviye dirençli depresyonda antidepresanlara ekleme tedavisi olarak onay aldı. Bir kaç gün önce de tek başına da ABD’nde onay aldı. Fakat bu metaanalize göre esketaminin etki büyüklüğü dirençli depresyonda düşük, nüks yüksek ! https://t.co/PL9Xebu70h
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
https://t.co/Uu206Y82WJ
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
RT @chrisaikenmd: Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to an…
Metaanalysis raises concern about esketamine (Spravato): > Only 1/5 trials positive @4 wk > Small benefit, similar to antipsychotic aug, declines over time > Maintenance trials may be biased by WD effects (49% of relapses occurred in 1st 4 wk after stop) https://t.co/NjeEEmNgPO https://t.co/4KEA5rDxhv
MA: A weak positive effect for depression was observed with IN esketamine as an add-on to ADs in TRD (ES range= 0.15–0.23 at weeks 2–4), similar to augmentation with SGAs. The effect size concerning suicidality was not significant at any time point https://t.co/NNdqQmvmjU
Metaanalysis raises concern about #esketamine (Spravato): > Only 1 of 5 trials positive at 4 wk > Small benefit, similar to antipsychotic aug, declines over time > Maintenance trials may be biased by WD effects (49% of relapses occurred in 1st 4 wk after stop) pubmed.ncbi.nlm.nih.gov/39876682
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry https://t.co/aRvSezG3bW
Prometedora aunque muy cara, en este Meta Análisis queda claro que todo quedó en promesas. Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis | American Journal of Psychiatry https://t.co/SVSk3N5iSo
@chrisaikenmd But then this lukewarm study comes along today. What gives with this, doctor? https://t.co/yyVnFd2vt6